TSE:NRX Stock Latest News
Company AnnouncementsNurExone Shows Consistent Anti-Inflammatory Activity in Naïve Exosome Batches2d ago
Company AnnouncementsNurExone Doubles Exosome Output With Parallel Bioreactors, Advancing Modular Manufacturing Strategy1w ago
Company AnnouncementsNurExone Advances Exosome Therapy After Positive Optic Nerve Data3w ago
Company AnnouncementsNurExone Steps Up U.S. Push With Boston Life Sciences Events and Investor Campaign1M ago
Company AnnouncementsNurExone Shareholders Back Board, Clear Path for Potential 30-for-1 Share Consolidation1M ago
Company AnnouncementsNurExone advances exosome programs as R&D spend rises and new financing secured2M agoCompany AnnouncementsNurExone to Spotlight Exosome Platform at Moody Capital Disruptive Growth Conference2M ago
Company AnnouncementsNurExone Seeks Shareholder Approval for Share Consolidation to Support U.S. Listing Bid2M ago
Company AnnouncementsNurExone Raises C$1.07 Million in Private Placement to Support Regenerative Therapy Push2M ago- Company AnnouncementsNurExone Preclinical Data Bolster Neuroprotective Case for ExoPTEN in Spinal Cord Injury2M ago
Company AnnouncementsNurExone Strikes Exclusive U.S. GMP Exosome Manufacturing Pact with Made Scientific2M ago- Company AnnouncementsNurExone’s Exo-Top Signs LOI With BioXtek for U.S. Exosome Manufacturing Push6M ago
Company AnnouncementsNurExone Wins BOLD Healthcare Award and Hires IBN to Boost Investor Visibility7M ago
Company AnnouncementsNurExone Bolsters European Push and Balance Sheet With Strategic Hire and C$880K Financing7M ago
Company AnnouncementsNurExone to Spotlight Exosome Platform at Key 2026 Conferences as Executive Departs8M ago
Company AnnouncementsNurExone Bolsters Exosome Manufacturing Consistency Ahead of Clinical Push8M ago- Company AnnouncementsNurExone Adds Healthcare Heavyweight Eyal Gabbai to Board as It Advances Exosome Platform9M ago
Company AnnouncementsNurExone Exosomes Show Strong Anti-Inflammatory Effect, Outperform Commercial Rival in Lab Tests10M ago